Publisher
Springer Nature Switzerland
Reference44 articles.
1. Akbar, S., Subhan, F., Karim, N., Aman, U., Ullah, S., Shahid, M., … Sewell, R. D. E. (2017). Characterization of 6-methoxyflavanone as a novel anxiolytic agent: A behavioral and pharmacokinetic approach. European journal of pharmacology, 801, 19–27. Retrieved from
2. Alonso, J., & Lépine, J. P. (2007). Overview of key data from the European Study of the Epidemiology of Mental Disorders (ESEMeD). J Clin Psychiatry, 68 Suppl 2, 3–9.
3. Alonso, J., Liu, Z., Evans-Lacko, S., Sadikova, E., Sampson, N., Chatterji, S., … Thornicroft, G. (2018). Treatment gap for anxiety disorders is global: Results of the World Mental Health Surveys in 21 countries. Depress Anxiety, 35(3), 195–208. https://doi.org/10.1002/da.22711
4. Baldwin, D. S., Ajel, K., Masdrakis, V. G., Nowak, M., & Rafiq, R. (2013). Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat, 9, 883–892. https://doi.org/10.2147/ndt.S36453
5. Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., … Wittchen, H. U. (2014). Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol, 28(5), 403–439. https://doi.org/10.1177/0269881114525674